Johnson & Johnson's Q2 2009 earnings call revealed a mixed performance, with total sales decreasing by 7.4% year-over-year due to currency fluctuations and generic competition in the pharmaceutical segment. However, the company's operational sales growth was -1.4%, and management expressed confidence in the underlying growth of the business, driven by new product launches and advancements in the pipeline. The company also announced several acquisitions and partnerships, including a deal with Elan Corporation, which demonstrates its commitment to investing in growth opportunities.

[-1]